All News


Will Roche get what it paid for?

Beyond its blockbuster drugs Genentech has a commodity rare in a large company – an entrepreneurial culture. Can Roche preserve this?

The trouble with Framework Programmes

A quietly published review has criticised FP6 as too bureaucratic, and for not reaching out to the private sector. But are these failings being perpetuated in FP7?